Kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy based on multiple small VOIs

被引:0
|
作者
Kapidzic, Selma Curkic [1 ,2 ,3 ]
Gustafsson, Johan [1 ]
Larsson, Erik [2 ]
Jessen, Lovisa [1 ]
Gleisner, Katarina Sjogreen
机构
[1] Lund Univ, Med Radiat Phys, Lund, Sweden
[2] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Radiat Phys, Malmo, Sweden
[3] Skanes Univ Sjukhus, Barngatan 4, S-22185 Lund, Sweden
关键词
177; Lu-PRRT; Quantitative SPECT; Dosimetry; Kidneys; RECEPTOR RADIONUCLIDE THERAPY; PATIENT-SPECIFIC DOSIMETRY; IMAGE-BASED DOSIMETRY; NEUROENDOCRINE TUMORS; SPECT; ACCELERATION;
D O I
10.1016/j.ejmp.2024.103335
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The aim was to investigate the use of multiple small VOIs for kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy. Method: The study was based on patient and simulated SPECT images in anthropomorphic geometries. Images were reconstructed using two reconstruction programs (local LundaDose and commercial Hermia) using OS -EM with and without resolution recovery (RR). Five small VOIs were placed to determine the average activity concentration (AC) in each kidney. The study consisted of three steps: (i) determination of the number of iterations for AC convergence based on simulated images; (ii) determination of recovery -coefficients (RCs) for 2 mL VOIs using a separate set of simulated images; (iii) assessment of operator variability in AC estimates for simulated and patient images. Five operators placed the VOIs, using for guidance: a) SPECT/CT with RR, b) SPECT/CT without RR, and c) CT only. For simulated images, time -integrated ACs (TIACs) were evaluated. For patient images, estimated ACs were compared with results of a previous method based on whole -kidney VOIs. Results: Eight iterations and ten subsets were sufficient for both programs and reconstruction settings. Mean RCs (mean +/- SD) with RR were 1.03 +/- 0.02 (LundaDose) and 1.10 +/- 0.03 (Hermia), and without RR 0.91 +/- 0.03 (LundaDose) and 0.94 +/- 0.03 (Hermia). Most stable and accurate estimates of the AC were obtained using five 2mL VOIs guided by SPECT/CT with RR, applying them to images without RR, and including an explicit RC for recovery correction. Conclusion: The small VOI method based on five 2-mL VOIs was found efficient and sufficiently accurate for kidney dosimetry in [ 177 Lu]Lu-DOTA-TATE therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Johannes Zellmer
    Hsi-Yu Yen
    Lena Kaiser
    Erik Mille
    Franz Josef Gildehaus
    Guido Böning
    Katja Steiger
    Marcus Hacker
    Peter Bartenstein
    Andrei Todica
    Alexander R. Haug
    Harun Ilhan
    EJNMMI Research, 10
  • [32] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Zellmer, Johannes
    Yen, Hsi-Yu
    Kaiser, Lena
    Mille, Erik
    Gildehaus, Franz Josef
    Boening, Guido
    Steiger, Katja
    Hacker, Marcus
    Bartenstein, Peter
    Todica, Andrei
    Haug, Alexander R.
    Ilhan, Harun
    EJNMMI RESEARCH, 2020, 10 (01)
  • [33] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [34] Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
    Heribert Hänscheid
    Philipp E. Hartrampf
    Andreas Schirbel
    Andreas K. Buck
    Constantin Lapa
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 2566 - 2572
  • [35] Safety and Dosimetry of [177Lu]Lu-DOTA-TATE in Adolescent Patients With Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors or Pheochromocytomas and Paragangliomas
    Giraudet, A.
    Handkiewicz-Junak, D.
    Hladun, R.
    Laetsch, T. W.
    Sorge, C.
    Sparks, R.
    Xu, L.
    Perraud, K.
    Kollar, G.
    Khanshan, F.
    Blumenstein, L.
    Brouri, F.
    Gaze, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S664 - S664
  • [36] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    CANCERS, 2022, 14 (03)
  • [37] Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
    Haenscheid, Heribert
    Hartrampf, Philipp E.
    Schirbel, Andreas
    Buck, Andreas K.
    Lapa, Constantin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (08) : 2566 - 2572
  • [38] Comparison of Voxel S-values and Monte Carlo Simulation in [177Lu]Lu-DOTA-TATE Quantification for Patient-Specific Dosimetry
    Rodrigues, C.
    Ferreira, P.
    Oliveira, F. P. M.
    Silva, A.
    Peralta, L.
    Costa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S75 - S75
  • [39] Radioligand Therapy with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Mroz, Adrianna
    Zmudzki, Wawrzyniec
    Kaminski, Grzegorz
    PHARMACEUTICALS, 2023, 16 (09)
  • [40] S-phase enrichment by hydroxyurea treatment enhances [177Lu]Lu-DOTA-TATE uptake in vitro
    Cheng, J.
    Livieratos, L.
    Terry, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S57 - S57